title: Selective destruction of nigrostriatal dopaminergic neurons does not alter [3H]-ryanodine binding in rat striatum.
abstract: Dopamine nigrostriatal neurons are important for motor control and may contain a particularly dense population of ryanodine receptors involved in the control of dopamine release. To test this hypothesis, we used a classical model of unilateral selective lesion of these neurons in rats based on 6-hydroxydopamine (6-OHDA) injection into the substantia nigra. Binding of [3H]-GBR 12935, used as a presynaptic marker since it labels specifically the dopamine uptake complex, was dramatically decreased by 83-100% in striatum homogenates after 6-OHDA lesion. On the contrary, no reduction of [3H]-ryanodine binding was observed. The present data indicate that [3H]-ryanodine binding sites present in rat striatum are not preferentially localized in dopaminergic terminals.
authors.affiliation: Departamento de Farmacologia Básica e Clínica, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brasil. fnoel@pharma.ufrj.br
authors.forename: F
authors.initials: F
authors.lastname: Noël
authors.forename: M
authors.initials: M
authors.lastname: Geurts
authors.forename: J M
authors.initials: JM
authors.lastname: Maloteaux
mesh_terms: D018663:Adrenergic Agents / Q000494:pharmacology; D000818:Animals; D001971:Bromocriptine / Q000627:therapeutic use; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism*; D004298:Dopamine / Q000378:metabolism*; D018491:Dopamine Agonists / Q000627:therapeutic use; D008297:Male; D009459:Neuroleptic Malignant Syndrome / Q000188:drug therapy / Q000378:metabolism*; D009474:Neurons / Q000187:drug effects / Q000378:metabolism*; D016627:Oxidopamine / Q000494:pharmacology; D010879:Piperazines / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D019837:Ryanodine Receptor Calcium Release Channel / Q000378:metabolism*; D013378:Substantia Nigra / Q000187:drug effects / Q000378:metabolism
chemical_list: D018663:Adrenergic Agents; D018491:Dopamine Agonists; D010879:Piperazines; D019837:Ryanodine Receptor Calcium Release Channel; D001971:Bromocriptine; D016627:Oxidopamine; C044630:1-(2 (diphenylmethoxy)ethyl)-4-(3-phenylpropyl)piperazine; D004298:Dopamine